Dr. Reddy's Laboratories is currently trading at Rs. 1352.60, up by 12.35 points or 0.92% from its previous closing of Rs. 1340.25 on the BSE.
The scrip opened at Rs. 1358.25 and has touched a high and low of Rs. 1358.75 and Rs. 1340.20 respectively. So far 80279 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1414.40 on 29-Jun-2026 and a 52 week low of Rs. 1080.05 on 23-Jul-2026.
Last one week high and low of the scrip stood at Rs. 1390.70 and Rs. 1,303.95 respectively. The current market cap of the company is Rs. 112948.94 crore.
The promoters holding in the company stood at 26.63%, while Institutions and Non-Institutions held 52.18% and 10.08% respectively.
Dr. Reddy's Laboratories has secured tentative approval for its injectable lenacapavir used for reducing HIV-1 risk from United States Food and Drug Administration (USFDA). The approval was granted under the USFDA’s President's Emergency Plan for AIDS Relief (PEPFAR) programme. The USFDA decision provides a regulatory basis for further steps, including World Health Organization (WHO) pre-qualification and national regulatory approvals.
Under an existing agreement, the injectable will be made available at $40 per person per year across 120 countries outside the US covered by Gilead Sciences' voluntary licence. The first supplies are expected to reach countries before the end of 2026, with a broader rollout across eligible nations planned in 2027.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
